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Abstract
Objective: The aim of this study is to evaluate the efficacy and safety of a topical formulation containing lidocaine plus
diclofenac (CLIFE1) compared to lidocaine (CLIFE2), to decrease pain in benign anorectal surgery (BARS) to date not
evaluated. More than 50% of patients undergoing BARS, especially hemorrhoidectomy, suffer from moderate and
severe postoperative pain. This remains an unresolved problem that could be addressed with the new CLIFE1 topical
treatment.
Methods: A multicenter, randomized double-blind, active-controlled parallel-group superiority trial, was conducted in
two Spanish hospitals. Patients undergoing BARS (hemorrhoids, anal fistula and anal fissure) were randomized at the
end of surgery at a 1:1 ratio to receive first dose either CLIFE1 (n= 60) or CLIFE2 (n= 60) anorectal topical treatment,
and after every 12 h for the first three postoperative days and once a day from the fourth to sixth. The primary
outcome was average of pain decrease after topical treatment, measured with visual analogue scale (VAS) by the
patients themselves, the evening in the surgery day and four times daily for the first three postoperative days.
Results: The results of 120 patients included out of 150 selected undergoing BARS show a decrease in pain after
CLIFE1 topical treatment (7.47 ± 13.09) greater than with CLIFE2 (4.38 ± 6.75), difference −3.21 95% CI (−5.75; −0.68),
p= 0.008, decreasing significantly postoperative pain ( ≥ 9 mm, VAS) in 35% of patients undergoing benign anorectal
surgery, compared to 18.33 % treated with lidocaine.
Conclusions: The CLIFE1 topical treatment shows better analgesic efficacy than CLIFE2 in BARS.
Introduction
Reducing the high incidence of pain is a priority of
health plans in Western countries1,2. More than 70% of
patients undergoing surgery suffer moderate or severe
postoperative pain, according to the surgical procedure3
even when they receive painkillers4. In benign anorectal
surgery 50% of patients suffer from a higher level of pain
than expected5,6 after hemorrhoidectomy7.
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Sustained episodes of moderate and severe pain after
surgery increase morbidity8 and risk to develop a chronic
postoperative pain syndrome9,10. Despite postoperative
pain remains an important unresolved issue11,12 that
causes expense and patient dissatisfaction13, this problem
has been addressed in the same manner over the last
twenty years 14. Therefore this situation calls for multi-
modal pain management15, choosing medication, dosing
regimens and route of administration in an individualized
way to optimize efficacy and minimize adverse effects16, as
the Practice Guidelines for Acute Postoperative Pain of
the American Society of Anesthesiologists (ASA)
recommends17.
Given postoperative pain in benign anorectal surgery
(BARS) has not been solved in its entirety, some authors
have used balms, creams and ointments18 that contain
nifedipine19, diltiazem20, botulinum toxin21, or nitrogly-
cerin22 in order to reduce spasms of the anal sphincter. It
has also been used topical metronidazole ointment to
decrease exacerbated pain from the third day onwards
post-hemorrhoidectomy23. All these topical treatments
help to reduce pain however they are not exempt from
side effects such as headache, denervation, orthostatic
hypotension or bradycardia24,25.
Other authors compare topical lidocaine alone26,27 or
lidocaine plus prilocaine (EMLA cream)28 with a rectal
diclofenac suppository administered in one dose by the
surgeon at the end of hemorrhoidectomy. The results
show higher analgesic efficacy for EMLA after the first
two hours post-hemorrhoidectomy, however diclofenac is
more effective in the evening after surgery and in the
morning of the day after, as well as in reducing urinary
retention events29.
Both lidocaine30 and diclofenac31–33 have analgesic,
anti-inflammatory, and antibiotic effects. These properties
are suitable to treat three postoperative pain components
in BARS: nociceptive pain (somatic and visceral),
inflammatory, and pain provoked by superinfection of the
contaminated area34.
Postoperative pain management can be optimized by
taking into consideration its physiopathology depending
on the surgical procedure and the operated area. Thus
including topical treatments within multimodal analgesic
management in BARS aligns with PROSPECT group
recommendations. These aim to improve postoperative
pain analgesia and minimize side effects such as somno-
lence, dizziness, sickness and vomiting according to
patient preferences.
Evidence shows that current postoperative pain man-
agement can be optimized by taking into account the pain
causes and the operated area in each surgical procedure as
the PROSPECT group recommends35. This new approach
that incorporates topical analgesia within the multimodal
strategy respecting patient preferences (like having a slight
discomfort but without side effects such as drowsiness,
dizziness or vomiting)36 meets their recommendations.
Since lidocaine and diclofenac have a synergistic
analgesic effect37 and its combination has not been eval-
uated in postoperative pain so far, the double-blind ran-
domized clinical trial “CLIFE-2010FV” was introduced to
demonstrate that a fixed-dose combination of diclofenac
sodium plus lidocaine (CLIFE1), is more effective than
lidocaine alone (CLIFE2) to treat pain after BARS during
the first postoperative week.
Methods
Ethics and Trial Registration
The CLIFE-2010FV clinical trial was conducted in 2
hospital centers [Viladecans Hospital (HV) and Bellvitge
University Hospital (HUB)] from August 2011 to
December 2013. The study was approved by the Ethics
Committee of HUB (Comité Ético del HUB) and the
Spanish Agency of Medicines and Medical Devices (la
Agencia Española del Medicamento y Productos Sanitar-
ios-AEMPS). All participants signed the informed consent
form. The statistical plan and protocol are available in
Supplement 1 and 2, respectively.
Study Design
The CLIFE-2010FV study design includes a multicenter,
double-blind, randomized controlled clinical trial with
parallel group superiority of CLIFE1 topical treatment
(lidocaine plus diclofenac) versus CLIFE2 topical treat-
ment (lidocaine) for postoperative pain treatment in
benign anorectal surgery (BARS). The randomization was
centralized and based on a computer-generated list with a
1:1 randomization ratio in blocks of 4 and stratified by
center and surgery procedure to obtain two balanced
arms, minimizing the confounding factors due to different
levels of pain after BARS (fissurectomy, fistulectomy and
hemorrhoidectomy surgeries).
Participants/Patients
All adult patients who participated in the study met the
following inclusion criteria: patients undergoing
BARS–hemorrhoidectomy (Milligan-Morgan technique),
anal fissure (internal lateral sphincterotomy) or fistula
surgery (fistulectomy) under lidocaine spinal anesthesia
according to standard protocol. Patients with one of the
following exclusion criteria were removed: pregnancy,
incomplete spinal anesthesia, general anesthesia, the
presence of allergy or intolerance to topical treatment
ingredients, gastrointestinal inflammatory illness or active
channel blockers).
Intervention
The patients were randomized to receive one of the two
topical treatments in semi-solid formulation with an
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application on the anorectal area in an identical manner
for both study groups. CLIFE1 topical treatment was
composed of 15 grams of a fixed-dose combination con-
taining 0.5% sodium diclofenac and 2% lidocaine (hydro-
chloride), and CLIFE2 topical treatment consisted of 15
grams of 2% lidocaine (hydrochloride). The study starts
when the surgeon administrates the first topical treatment
dose at the end of surgery, the subsequent doses are
administrated by the patient in an identical manner as
follows: once in the evening of the surgery day, twice daily
(morning and evening) for the first three postoperative
days, and one dose in the evening from the fourth to the
sixth. In addition to the topical study treatment, all
patients received the usual postoperative analgesia if there
was any discomfort or pain (paracetamol / metamizole
every 8 h, dolantine parenterally as rescue medication
during hospitalization and trometamol orally at home).
Randomization was blinded for patients, surgeons,
anesthesiologists and nurses who participated in the trial.
They all followed the protocol, recorded data that were
checked by external monitoring. All patients followed
identical protocol of hygiene, postoperative surgical
wound care and diet to avoid constipation.
Primary Efficacy Outcome
The primary variable is the mean of reduction in pain
(pre-post topical treatment). Pain reduction is measured
by calculating the difference in millimeters between the
pain evaluated by the patient before and after each dose of
topical treatment for the first three postoperative days and
in the afternoon of the day of surgery, with the visual
analog scale (VAS) (score range from 1 to 100mm)38 and
registered by the patient in the Self-Evaluation Pain
Journal (Cuaderno de Autoevaluación del Dolor, CAD).
Moreover, considering clinically relevant a pain reduction
of at least 9 mm (value greater than 30% of the average
VAS across all patients studied)39–41.
Secondary Outcomes
The following secondary variables were considered:
- Area under the curve (AUC) of the pain reduction on
the first six postoperative days; from the fourth to the
sixth day.
- Probability of reducing the pain intensity with the topical
treatment, from severe (VAS > 75) to moderate (VAS 45–74)
or mild (0–44)42. The pain relief after every topical treatment
dose according to this relief scale [no relief (1), mild (2),
moderate (3), important (4), complete (5)].
- Satisfaction survey in regard to the topical treatment
effectiveness.
- Oral and parenteral analgesia consumption as usual
and the rescue medication, at the hospital and at home.
- Clinical Global Impression Scale43 evaluation by the
researcher.
- Time to the first void (TTFV) and adverse effects (AE),
related or not with the topical treatment.
Data Collection
Patients scored pain intensity according to VAS scale,
daily before and 45 min after the topical treatment (a
timer was used after the topical treatment was applied),
during the first postoperative week and they registered it
in the Self-Evaluation Pain Journal (CAD).
The researcher during the final trial visit (on the seventh
day) checked as follows: pain relief scores after every
topical treatment dose, the TTFV, the patient satisfaction
survey, the medication consumption of the topical treat-
ment study, oral and parenteral analgesia and rescue
medication, as well as concomitant medication according
to specific patient conditions. The researcher also assessed
the clinical Global Impression score, adverse effects, phy-
sical exam results, lab tests and electrocardiogram (EKG).
Sample Size
Sample size was calculated to detect a reduction of pain
intensity of 20 units (SD 30) considering VAS scale (score
range from 1 to 100), during the first three postoperative
days with a two-sided for 5% significance level and a
power of 80%, a sample size of 60 patients per group was
necessary given an anticipated dropout rate of 10%.
Statistical Methods
The means (standard deviation), the absolute fre-
quencies and percentages were calculated to describe the
quantitative and qualitative variables, respectively.
A comparative analysis was conducted to evaluate dif-
ferences between the quantitative variables of the two
groups (CLIFE1, lidocaine plus diclofenac/CLIFE2, lido-
caine) based on the Mann–Whitney U test. Analysis of the
qualitative variables based on the Chi-squared indepen-
dence test and the calculation of a 95% confidence interval
(95% CI) for parameters corresponding to the effect.
In order to evaluate the probability of change from a
higher pain level to a lower after topical treatment, stra-
tification was predetermined according to a three-level
pain score range (0–44, 45–74, and>75) and measured
with VAS scale. Relative risk (RR) of the likelihood of
improvement or get worse was calculated to compare the
efficacy of the two topical treatments. These probabilities
were obtained calculating the number of times that a
decrease of pain was observed (from severe to moderate
or mild pain and from moderate to mild pain), comparing
the probability of progressing from a higher pain level to a
lower pain level in each of both groups.
The area under the curve (AUC) of pain reduction
according to VAS scale (0–100) was calculated for each
patient, using the trapezoidal rule, analyzing the differ-
ence between groups using a Mann–Whitney test.
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Cumulative distribution curves based on the metho-
dology proposed by Farrar41 were drawn for each group
during the first three and six postoperative days to com-
pare the efficacy of topical treatment between both groups
CLIFE1 and CLIFE2. On the x-axis, cut-off points (%)
were represented based on 100% in reference to the
maximum decrease of pain intensity in VAS scale (before/
after topical treatment). On the y-axis, representing the
proportion of patients (responders). The difference on the
proportion of responders between both groups was spe-
cifically assessed at a 30% of pain decrease using a chi-
squared test.
A logistic regression model was constructed to analyze
the subgroups according to surgery type and the relative
risk of reducing pain in at least 9 mm after topical treat-
ment, adjusted by gender and surgery type. A chi-squared
test was also used to assess significance.
A 5% significance level (p= 0.05) established and 95%
CI were conveniently computed.
All analyses were performed using the R program. The
efficacy analysis of the primary variable in per-intent-to-
treat population was carried out, as well as a sensitivity
analysis in per-protocol population.
Results
A total of 120 patients out of 150 selected undergoing
BARS were included, of which 12 were excluded (6 per
group) from the efficacy analysis per protocol (PP) (refer
to the flow diagram of the study in Fig. 1).
The demographic and clinical baseline characteristics,
as well as surgery type were distributed homogeneously in
both groups, except gender (Table 1).
The postoperative pain average of the total population
included and the patients undergoing hemorrhoidectomy
was below 30mm (VAS scale 1–100).
Primary Outcomes
The average reduction in pain intensity (VAS scale)
after topical treatment in the three first post-surgery days,
is higher with the topical treatment CLIFE1 (diclofenac
plus lidocaine) (7.47 ± 13.09) than topical treatment
CLIFE2 (lidocaine) (4.38 ± 6.75), difference: −3.21, 95%
confidence interval (95% CI): −5.75; −0.68, p= 0.008,
adjusted p= 0.01.
The Area under the curve (AUC) analysis of pain
reduction (VAS) post-treatment in the first three post-
operative days also shows greater efficacy for CLIFE1 than
for CLIFE2 in the intention-to-treat analysis (difference
−17.53; 95% CI −33.20; −1.84; p= 0.02) (Table 2).
In the Fig. 2 it is observed that the relative risk of
decreasing pain in at least 9 mm is almost double with the
topical treatment CLIFE1 in the first three postoperative
days and double in the first six days compared to the
topical treatment CLIFE2 (in per-protocol population).
The data shows that 35% of patients treated with topical
treatment CLIFE1 had a statistically significant reduc-
tion ≥ 9 mm compared to 18.33% of patients treated with
CLIFE2, RR= 1,91, 95% CI (1.01; 3.60), p= 0.03)
(Table 3).
The maximum pain reduction value obtained is 83 mm
of VAS (100%). The proportion of patients that show a
greater cumulative reduction of pain (%) after the topical
treatment CLIFE1 is always higher for any value of pain
reduction than after the topical treatment CLIFE2 in the
first three and six postoperative days (in the Fig. 3 it is
observed by way of example: 30% of pain reduction affects
40% of patients treated with CLIFE1 and 20% of patients
with CLIFE2, being this difference statistically significant,
p= 0.02)41.
The probability of progressing from a high pain level to
a lower, according to VAS cut-offs (pain mild ≤ 44;
moderate 45-74 and severe ≥ 75), is 1.43-fold higher in
CLIFE1 topical treatment than in CLIFE2 (RR= 1.43, 95%
CI 0.98; 2.09; p= 0.06).
Similar results are observed when the population is
analyzed per-protocol. Results obtained when considering
pain improvement at baseline and after day 1 to 6 are
shown in Supplementary Table 1, likewise VAS average
values on each of the timed points evaluated (before and
45min after topical treatment) are shown in Supple-
mentary Table 2, both suggesting an accumulative effect.
Secondary Outcomes
The average reduction in pain level, after topical treat-
ment in the first six postoperative days, is significantly
higher in the group treated with CLIFE1 (8.08 ± 14.50)
than in the group CLIFE2 (4.26 ± 6.55) difference −3.92;
95% CI −6.62; −1.22; p= 0.004.
In the AUC analysis of pain reduction (VAS) after
topical treatment in the first six postoperative days,
showing also greater efficacy for CLIFE1 than for
group CLIFE2, difference −32.72; 95% CI −57.04; −8.40;
p= 0.006.
Moreover, the proportion of patients who show greater
reduction in pain intensity for any difference evaluated,
was higher in treatment CLIFE1 than in CLIFE2 for the
first six days after surgery (Fig. 3)41
A higher reduction in pain levels is consistently
observed after all the administrations of topical treatment
CLIFE1 in BARS, without any change when stratifying by
gender.
Analysis of subgroups by surgery
Patients undergoing hemorrhoidectomy have a higher
postoperative pain level and also show greater pain
reduction with the topical treatment CLIFE1 than with
CLIFE2, difference −4.11, 95% CI −7.94, −0.29, p= 0.04,
compared to those undergoing fissurectomy or
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fistulectomy, in which there is no statistically significant
difference between topical treatments (Table 4).
The stratified analysis presents similar efficacy in both
genders, however it does not have sufficient statistical
power to assess whether different levels of efficacy are
associated to gender.
When adjusting by gender and surgery type displays a
significant pain reduction of at least 9mm of VAS, but only
in women undergoing hemorrhoidectomy (73% with the
topical treatment CLIFE1 compared to 32% with CLIFE2 [RR
2.30, 95% CI 1.08;4.90, p= 0.03] using data from the first six
days.
The average perceived relief of pain is similar in patients
in both groups. However, when pain level before topical
treatment was between 40 and 70mm (VAS scale),
the relief level was significantly higher for the CLIFE1
group.
The clustering of patients who suffer a moderate or total
pain relief on the seventh day reveal that 91% of the
patients belong to CLIFE1 and 74% to CLIFE2 (p= 0.02).
Fig. 1 Flow diagram Assessed for eligibility (n= 150). Flowchart of patients through the trial
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There was no significant difference in the evaluation of
the Global Clinical Impression scale or the use of rescue
analgesia between the two groups.
The satisfaction survey does not show statistically sig-
nificant differences between topical treatments (90%
satisfied or very satisfied in both groups), however there is
a higher percentage of patients who report painless or
slight discomfort in the group CLIFE1 (17%) compared to
CLIFE2 (13%), while the 1% of dissatisfied patients
belonged to the latter.
Time to First Void (TTFV)
There is no statistical significant difference in the
TTFV between topical treatment groups [TTFV CLIFE1
= 282.66 (SD,132.47) minutes, TTFV CLIFE2= 280.49
(SD, 132.47) minutes, p < 0.53], no correlation observed
Table 1 Demographic and clinical characteristics of the patients
Characteristics Overall (n= 120) CLIFE1 (Lidocaine plus diclofenac) (n= 60) CLIFE2 (Lidocaine) (n= 60) p-value
Gender
Male, n (%) 72 (60.00) 30 (50.00) 42 (70.00) 0.04a
Female, n (%) 48 (40.00) 30 (50.00) 18 (30.00)
Caucasian, n (%) 116 (96.6) 56 (93.33) 60 (100.00) 0.13a
Age, year mean (SD) 47.55 (12.39) 47.37 (11.79) 47.73 (11.79) 0.72b
BMI, kg/m2, mean (SD) 26.46 (5.30) 25.62 (5.99) 27.31 (5.99) 0.07b
ASA
I, n (%) 56 (46.66) 30 (50.00) 26 (43.33) 0.24a
II, n (%) 62 (51.66) 28 (46.67) 34 (56.66)
III, n (%) 2 (1.66) 2 (3.33) 0 (0.00)
Type of surgery, n (%)
Hemorrhoids, n (%) 73 (60.83) 36 (49.32) 37 (50.68) 0.66c
♀ 34 (46.57) 22 (64.71) 12 (35.29)
♂ 39 (53.42) 14 (35.90) 25 (64.10)
Anal fistula, n (%) 34 (28.33) 16 (47.06) 18 (52.94)
♀ 11 (32.35) 6 (54.55) 5 (45.45)
♂ 23(67.64) 10 (43.48) 13 (56.52)
Anal fissure, n (%) 13 (10.83) 8 (61.54) 5 (38.46)
♀ 3 (23.07) 2 (66.67) 1 (33.33)
♂ 10 (76.92) 6 (60.00) 4 (40.00)
Surgery time, min, mean (SD) 18.79 (10.81) 19.92 (10.16) 17.67 (10.16) 0.25b
Spinal lidocaine, mg, mean (SD) 29.03 (11.99) 29.53 (12.21) 28.53 (12.21) 0.55b
SD standard deviation, BMI body mass index, ASA American Society of Anesthesiology, ♀ Female, ♂ Male
aObtained with the Chi-squared test (Pearson)
bObtained with the Mann–Whitney U test
cObtained with the Chi-squared independence test
Table 2 Effectiveness analysis, reduction of pain after topical treatment, according to VAS
CLIFE1 (Lidocaine plus diclofenac) CLIFE2 (Lidocaine) Difference (95% CI) p-valuea
Intention-to-treat population (n= 60) (n= 60)
Reduction in pain after topical treatment (VAS)
First 3 postoperative days, mean (SD) 7.47 (13.09) 4.38 (6.75) −3.21 (−5.75; −0.68) 0.008
First 6 postoperative days, mean (SD) 8.08 (14.50) 4.26 (6.55) −3.92 (−6.62; −1.22) 0.004
Reduction in pain after topical treatment (AUC)
First 3 postoperative days, mean (SD) 45.69 (45.15) 28.16 (41.51) −17.53 (−33.20; −1.84) 0.02
First 6 postoperative days, mean (SD) 73.10 (74.77) 40.38 (58.72) −32.72 (−57.04; −8.40) 0.006
Per-protocol population (n= 54) (n= 54)
Reduction in pain after topical treatment (VAS)
First 3 postoperative days, mean (SD) 7.71 (13.20) 4.9 (5.96) −2.82 (−5.39; −0.24) 0.03
First 6 postoperative days, mean (SD) 8.4 (14.73) 4.76 (5.72) −3.65 (−6.42; −0.89) 0.01
Reduction in pain after topical treatment (AUC)
First 3 postoperative days, mean (SD) 47.05 (46.05) 30.71 (38.12) −16.34 (−32.47; −0.20) 0.047
First 6 postoperative days, mean (SD) 75.80 (76.47) 43.94 (52.95) −31.86 (−56.98; −6.72) 0.01
SD standard deviation, AUC area under the curve, VAS visual analog scale
aObtained from Mann–Whitney U test
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between TTFV and pain level. Nevertheless, TTFV
was significantly lower in patients undergoing
hemorrhoidectomy (three hemorrhoids) with topical
treatment CLIFE1 than with CLIFE2 [CLIFE1= 241.5 ±
131.95 min, p < 0.05; TTFV CLIFE2= 473.67 ± 131.95
min].
Safety Evaluation
Both topical treatments are safe from the day of surgery
until the seventh postoperative day. Nobody in either
group had any adverse effects related with the topical
treatment nor any sequels.
Discussion
The results of this clinical trial show that the topical
treatment with a combination of a non-steroidal anti-
inflammatory drug (NSAID) -diclofenac sodium plus a
local anesthetic -lidocaine (CLIFE1) presents greater
analgesic efficacy than the topical treatment with lido-
caine alone (CLIFE2) during the first three postoperative
days in benign anorectal surgery (BARS) and throughout
the entire first week.
It should be highlighted the consistency of efficacy
results that display analgesic advantage of the topical
treatment CLIFE 1, exhibiting a greater pain reduction for
any cut-off point, a larger percentage of patients who
diminish 20% of pain intensity, (61% in patients with
CLIFE1 treatment versus 32% of patients with CLIFE2
treatment, during first postoperative week)41 and a higher
percentage of patients who reduce pain intensity in 9 mm
or more of VAS (35% of patients in CLIFE1 versus 18.3%
in CLIFE2)39,40.
The topical treatment CLIFE1 capitalizes on the
analgesic synergy37, anti-inflammatory, and anti-microbial
action of lidocaine and diclofenac30–33 to prevent sus-
tained episodes of moderate and severe pain in hemor-
rhoids surgery, which is caused by the nociceptive
stimulation of the surgical incision, its inflammation, the
anal sphincter spasm and bacterial superinfection.
The new topical analgesic CLIFE1 is an instrument that
allows postoperative analgesia specific in BARS, as it
exhibits greater efficacy in painful surgical procedures like
hemorrhoidectomy, in which postoperative pain remains
an unsolved problem and affects more than 50% of
patients, who would benefit from the topical treatment
that addresses the problematic of the surgical wound, as
the group PROSPECT recommends35.
There are no available studies with the new topical
treatment CLIFE1 in BARS. However, there are studies in
which topical lidocaine shows greater pain reduction than
placebo, and combined with prilocaine (EMLA cream)28
provides earlier analgesia (two hours after the surgery)
than a single dose of diclofenac post-hemorrhoidectomy.
Likewise, diclofenac presents more effective late analgesia
in the evening of surgery day and the day after. These
results suggest that the analgesic superiority shown by the
new topical treatment CLIFE1 compared to CLIFE2
(lidocaine) is underestimated, since lidocaine has an
analgesic effect unlike a placebo. Thus the topical
Table 3 Effectiveness analysis, reduction of pain after topical treatment ≥ 9mm VAS
CLIFE1 (Lidocaine plus diclofenac) CLIFE2 (Lidocaine) RR (95% CI) p-valuea
Intention-to-treat population (n= 60) (n= 60)
Reduction in pain after topical treatment ≥ 9 mm VAS
First 3 postoperative days, n (%) 21 (35) 11 (18.33) 1.91 (1.01; 3.60) 0.03
First 6 postoperative days, n (%) 19 (31.67) 10 (16.67) 1.9 (0.97; 3.74) 0.05
Per-protocol population (n= 54) (n= 54)
Reduction in pain after topical treatment ≥ 9 mm VAS
First 3 postoperative days, n (%) 20 (37.03) 10 (18.52) 1.91 (1.03; 3.86) 0.03
First 6 postoperative days, n (%) 28 (33.33) 9 (16.67) 2 (1.01; 4.05) 0.04
VAS visual analog scale, RRrelative risk
aObtained from Chi-squared test
Fig. 2 Effectiveness analysis, reduction of pain after topical treatment ≥ 9
mm VAS
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treatment CLIFE1 use proposal combines the analgesic
effect of both early analgesia (lidocaine) and late analgesia
(diclofenac), which is beneficial to treat postoperative pain
after BARS.
The time to first void (TTFV) is similar in both topical
treatment groups. However, when stratifying by gender
and surgery type, women operated of three hemorrhoidal
packs who received topical treatment CLIFE1 significantly
diminish the TTFV (at almost half) versus the ones who
are under CLIFE2. These results coincide with other
studies which show a correlation between pain and mic-
turition difficulties44, as well as with one study that dis-
plays a pain reduction and minor percentage of post-
hemorrhoidectomy urinary retention, after a dose of rectal
diclofenac administered by the surgeon at the end of the
hemorrhoidectomy29.
The topical analgesia CLIFE1 has the advantage of being
self-administered either at the hospital or at home during
the first postoperative week, unlike the liposomal
bupivacaine infiltration after hemorrhoidectomy, which is
done by the surgeon in the operating room and its
analgesic efficacy is limited to the first 72 postoperative
hours with doses greater or equal to 260mg, which causes
greater side effects45,46.
The safety of the topical treatment CLIFE1 without side
effects and the easy handling process by the patient
themselves facilitate the treatment and the monitoring
over a longer period if need be. While also avoiding
hassles and complications derived from analgesic
techniques with perfusion by catheter in the surgical
wound15 which could require hospitalization or special
care at home16.
Patients were randomly assigned to each topical treat-
ment (CLIFE1 and CLIFE2) by surgery type to ensure an
even distribution in each of the three surgical procedures
(anal fistulectomy, anal fissurotomy and hemor-
rhoidectomy) with the same number of patients in each
treatment group.
Fig. 3 Cumulative distribution function curve for the two groups, during first three and six postoperative days41
Linares-Gil et al. Clinical and Translational Gastroenterology           (2018) 9:210 Page 8 of 11
Official journal of the American College of Gastroenterology
The number of patients undergoing hemorrhoidectomy
was sufficient to identify the differences between both
topical treatments studied, nonetheless the main limita-
tion of this trial stems from the insufficient number of
patients operated with fistulectomy and specially the
scarce number of patients undergoing anal fissurotomy, as
in none of these two surgical procedures the minimum
potency to detect differences was reached.
Another limitation is the comparison of the topical
treatment CLIFE1 under study with topical lidocaine
instead of comparing it with placebo. This was dismissed
in order to offer all patients some benefits with the topical
treatment, regardless of which treatment was adminis-
tered/assigned randomly and double-blind, which prob-
ably minimized the difference between topical treatments.
New studies with topical treatment CLIFE1 in BARS
that include a larger number of patients and centers must
be carried out to confirm and extrapolate our results to
other settings, as part of a multimodal analgesic strategy
to decrease postoperative pain, capitalizing on the
synergistic action between diclofenac and lidocaine37 with
minor adverse effects than the non-steroidal anti-inflam-
matory oral treatment47.
In conclusion, the new topical treatment with a formula-
tion containing diclofenac plus lidocaine (CLIFE1) is shown
to be safe and more effective than the topical treatment with
lidocaine alone (CLIFE2) in the first three postoperative days
and throughout the first week following BARS.
Study Highlights
WHAT IS CURRENT KNOWLEDGE
● In benign anorectal surgery (BARS) 50% of patients
suffer from a higher level of pain than expected,
after hemorrhoidectomy.
● Post-hemorrhoidectomy pain remains an unsolved
problem notwithstanding the treatment with
various balms, creams and ointments to reduce
spasms of the anal sphincter.
WHAT IS NEW HERE
● Topical analgesia with CLIFE1 gel (diclofenac plus
lidocaine) takes into consideration the
physiopatology of postoperative pain in BARS and
is more effective than lidocaine gel.
TRANSLATIONAL IMPACT
● Topical analgesia with CLIFE1 gel is clinically
indicated to decrease pain after BARS, increasing
patient satisfaction
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